Researchers at the University of Cincinnati have found that using a nanovesicle (a nanotechnology drug-delivery system) that contains a combination of a cell protein and a phospholipid can selectively target pancreatic cancer cells while sparing unaffected cells and tissues. By using both animal models and human cancer cells, the researchers demonstrated that the nanovesicles inhibited tumor growth and could potentially increase survival of pancreatic cancer patients.
An official website of the United States government.